All In Biotech

Drug Trial Radar · NCT00310180

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 10,273 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

10,273

Actual

Start

Apr 7, 2006

Primary completion

Mar 2, 2018

Study completion Sep 30, 2030

Sponsor

Sponsor type
NIH
First posted
Apr 3, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial studies the best individual therapy for women who have node-negative, estrogen-receptor positive breast cancer by using a special test (Oncotype DX), and whether hormone therapy alone or hormone therapy together with combination chemotherapy is better for women who have an Oncotype DX recurrence score of 11-25. Estrogen can cause the growth of breast cancer cells. Hormone therapy may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving hormone therapy together with more than one chemotherapy drug (combination chemotherapy) has been shown to reduce the chance of breast cancer recurrence, but the benefit of adding chemotherapy to hormone therapy for women with node-negative, estrogen-receptor positive breast cancer is small. New tests may provide information about which patients are more likely to benefit from chemotherapy.

Conditions

  • Breast Adenocarcinoma
  • Hormone Receptor Positive
  • Stage IA Breast Cancer AJCC v7
  • Stage IB Breast Cancer AJCC v7
  • Stage IIA Breast Cancer AJCC v6 and v7
  • Stage IIB Breast Cancer AJCC v6 and v7
  • Stage IIIB Breast Cancer AJCC v7

Interventions

  • AnastrozoleDrug

    Given PO

  • ExemestaneDrug

    Given PO

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • LetrozoleDrug

    Given PO

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • Radiation TherapyRadiation

    Undergo radiation therapy or partial breast irradiation

  • Tamoxifen CitrateDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 5-year Disease-free SurvivalTime frame: Assessed every 6 months within 5 years from registration and then annually up to 20 years, DFS rate estimated at 5 years

Locations

1,222 sites in 8 countries. Site status is shown where the registry gives one.

  • Northeast Alabama Regional Medical Center

    Anniston, Alabama

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Mobile Infirmary Medical Center

    Mobile, Alabama

  • Providence Hospital

    Mobile, Alabama

  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama

  • Alaska Regional Hospital

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • Banner Thunderbird Medical Center

    Glendale, Arizona

  • Banner Desert Medical Center

    Mesa, Arizona

  • Banner Baywood Medical Center

    Mesa, Arizona

  • Banner-University Medical Center Phoenix

    Phoenix, Arizona

  • Western Regional CCOP

    Phoenix, Arizona

  • Virginia G Piper Cancer Care-Del Camino

    Scottsdale, Arizona

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • Sparks Regional Medical Center

    Fort Smith, Arkansas

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas

  • NEA Baptist Memorial Hospital

    Jonesboro, Arkansas

  • Saint Bernards Regional Medical Center

    Jonesboro, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Arroyo Grande Community

    Arroyo Grande, California

  • PCR Oncology

    Arroyo Grande, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • East Bay Radiation Oncology Center

    Castro Valley, California

  • Eden Hospital Medical Center

    Castro Valley, California

  • Valley Medical Oncology Consultants-Castro Valley

    Castro Valley, California

  • Enloe Medical Center

    Chico, California

  • Community Cancer Institute

    Clovis, California

  • John Muir Medical Center-Concord

    Concord, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Bay Area Breast Surgeons Inc

    Emeryville, California

  • Kaiser Permanente-Fremont

    Fremont, California

  • Valley Medical Oncology Consultants-Fremont

    Fremont, California

  • Washington Health

    Fremont, California

  • California Cancer Associates for Research and Excellence (cCare)

    Fresno, California

  • Saint Jude Medical Center

    Fullerton, California

  • Glendale Memorial Hospital and Health Center

    Glendale, California

Showing 40 of 1,222 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.